

## Appendix 3Y's

PYC Therapeutics Limited (the '**Company**') submits the following Appendix 3Y's – change in Director's shareholdings in relation to Alan Tribe and Bernard Hockings following completion of the Retail Entitlement Issue.

**ENDS** For further information, please contact:

**INVESTORS**  
Rohan Hockings  
CEO  
info@pyctx.com

## About PYC Therapeutics

*PYC Therapeutics Limited (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.*

### Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 6151 0994

[pyctx.com](http://pyctx.com)

**PYC Therapeutics Limited**

ACN 098 391 961

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>PYC THERAPEUTICS LIMITED (FORMERLY PHYLOGICA LIMITED)</b>
<b>ABN</b>	<b>48 098 391 961</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Alan William Tribe</b>
<b>Date of last notice</b>	<b>12 November 2019</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	INDIRECT
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Tribe is a Director of Australian Land Pty Ltd, Delarge Investments Pty Ltd, Runcton Pty Ltd, Paghams Pty Ltd and Stockbridge Corporation Pty Ltd.
<b>Date of change</b>	28 November 2019
<b>No. of securities held prior to change</b>	671,479,497 ordinary shares
<b>Class</b>	Ordinary shares
<b>Number acquired</b>	123,184,263 ordinary shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$0.055 per ordinary share
<b>No. of securities held after change</b>	794,663,760 ordinary shares

---

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Retail entitlements issue underwritten shortfall
---	--

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>PYC THERAPEUTICS LIMITED (FORMERLY PHYLOGICA LIMITED)</b>
<b>ABN</b>	<b>48 098 391 961</b>

We, Phylogica Limited, give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Bernard Edward Frederick Hockings</b>
<b>Date of last notice</b>	<b>30 November 2018</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<b>INDIRECT</b> Dr Bernard Edward Hockings & Mrs Dianne Christine Hockings (B Hockings Private S/F 2 A/C)
<b>Date of change</b>	25 Nov 2019
<b>No. of securities held prior to change</b>	<b>DIRECT</b> - 103,351,783 Ordinary Shares <b>INDIRECT</b> Dr Bernard Edward Hockings & Mrs Dianne Christine Hockings (B Hockings private S/F 2 A/C) - 244,442,436 Ordinary shares Alexandra Hockings (Daughter) - 2,708,172 Ordinary shares James Hockings (Son) - 755,128 Ordinary shares
<b>Class</b>	Ordinary shares
<b>Number acquired</b>	302,052
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Shares issued under retail entitlement offer

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$16,612
<b>No. of securities held after change</b>	DIRECT - 103,351,783 Ordinary Shares INDIRECT - Dr Bernard Edward Hockings & Mrs Dianne Christine Hockings (B Hockings private S/F 2 A/C) 244,442,436 Ordinary shares - Alexandra Hockings (Daughter) 2,708,172 Ordinary shares - James Hockings (Son) 1,057,180 Ordinary shares

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

+ See chapter 19 for defined terms.